In conclusion, our data clearly demonstrate that fusing the 3E8 antibody to endostatin is a promising approach to extend the in vivo half-life of endostatin and to improve its anti-angiogenic and anti-tumor efficacy. Here, COL18A1 is linked to neoplasm.